Home News GTT slashes handset prices in “Pinktober” special
As GTT continues to observe its “Pinktober” campaign, the telecommunications giant will slash selected Alcatel handsets by 50 per cent up to October 20.
The company will introduce its “Pinktober” Alcatel special, which comes with some great deals. For “Pinktober”, GTT is slashing the price on the Alcatel Idol and the Alcatel Go Play by an unbelievable 50 per cent when customers activate a mobile monthly bundle for just $3499.
With its 13MP rear and 8MP front cameras; this piece sports a trendy touchscreen that delivers excellence on its 5.2-inch display with full high definition. “If persons are into creating awesome photo memories, this is the perfect phone to have. The pictures are of superb quality,” GTT noted.
The Alcatel Go Play is always ready for action. This mobile phone is waterproof, shockproof and dustproof, and comes with an 8MP rear and a 5MP front camera.
It also sports cool battery features with 500 hours of standby time, 8.3 hours talk time and 40 hours of non-stop music playback. During the promotion, the Alcatel Idol is available for $34,399 while the Alcatel Go Play is sold at $28,999.
In addition to the offers on handsets, GTT is urging its customers to be part of the inaugural “Pinktober” 5K/10K walk/run on October 21.
Register for $2000 and customers will get a free T-shirt to participate in the walk/run, 300MB data, and one ticket to the Travis Green Gospel, Chronixx Reggae or QQ Dancehall Concerts. The sum of $500 will go directly to the Guyana Cancer Foundation.
The promotion is done as the telecommunications company observes Breast Cancer Awareness and celebrates the lives of warriors who have fought and overcome the disease, and those still fighting valiantly for themselves and others.
GTT is pleased to partner with the Guyana Cancer Foundation in its amazing mission to raise awareness about this dreaded disease, to give back, and to show strong support for efforts aimed at early detection – a true way of taking the life out of cancer.